Metacrine Stock
Metacrine is a privately held biotech company
About Metacrine Stock
Metacrine is a privately held biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Investors
ARCH Venture Partners
Grail, Codiak Biosciences, Aledade, Metacrine, Beam Therapeutics, Mindstrong Health
Franklin Templeton Investments
LegalZoom, Sweetgreen, Sumo Logic, Rent the Runway, ClearMotion, Optoro, Metacrine, IEX Group
Funding History
| August 2015 | $36.0M |
|---|---|
| December 2017 | $22.0M |
| June 2018 | $65.0M |
Management
CEO
Neil McDonnell
CFO
Trisha Millican
CEO & President
Ken Song
Press
GlobeNewswire (press release) - Jun, 13 2018
FinSMEs (blog) - Jun, 8 2018
PR Newswire (press release) - Mar, 7 2018
The San Diego Union-Tribune - Dec, 7 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Metacrine or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
